Search research articles
Contact Us
Filters
Showing results (281-290 of 311) with videos related to
Page
of 32
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2002
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420
Sherif S Farag, Stephen L George, Edward J Lee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 27, 2009
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review
Denise M Oliansky, Joseph H Antin, John M Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia
Pierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, et al.
Hemasphere
|
March 15, 2021
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies
Jonathan Feld, Douglas Tremblay, Mikaela Dougherty, et al.
European Radiology
|
September 18, 2012
Fully automated derivation of coronary artery calcium scores and cardiovascular risk assessment from contrast medium-enhanced coronary CT angiography studies
Ullrich Ebersberger, Dov Eilot, Roman Goldenberg, et al.
Blood Advances
|
December 21, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
Amer M Zeidan, Isaac Boss, C L Beach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2002
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B
Lewis R Silverman, Erin P Demakos, Bercedis L Peterson, et al.
Blood Advances
|
December 31, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes
Amer M Zeidan, Isaac Boss, C L Beach, et al.
American Heart Journal
|
September 30, 2000
The mode selection trial (MOST) in sinus node dysfunction: design, rationale, and baseline characteristics of the first 1000 patients
G A Lamas, K Lee, M Sweeney, et al.
Psychological Science
|
February 26, 2016
When Is an Adolescent an Adult? Assessing Cognitive Control in Emotional and Nonemotional Contexts
Alexandra O Cohen, Kaitlyn Breiner, Laurence Steinberg, et al.
Page
of 32
Search research articles
Search
Showing results (281-290 of 311) with videos related to
Sort By:
Page
of 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2002
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420
Sherif S Farag, Stephen L George, Edward J Lee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 27, 2009
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review
Denise M Oliansky, Joseph H Antin, John M Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia
Pierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, et al.
Hemasphere
|
March 15, 2021
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies
Jonathan Feld, Douglas Tremblay, Mikaela Dougherty, et al.
European Radiology
|
September 18, 2012
Fully automated derivation of coronary artery calcium scores and cardiovascular risk assessment from contrast medium-enhanced coronary CT angiography studies
Ullrich Ebersberger, Dov Eilot, Roman Goldenberg, et al.
Blood Advances
|
December 21, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
Amer M Zeidan, Isaac Boss, C L Beach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2002
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B
Lewis R Silverman, Erin P Demakos, Bercedis L Peterson, et al.
Blood Advances
|
December 31, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes
Amer M Zeidan, Isaac Boss, C L Beach, et al.
American Heart Journal
|
September 30, 2000
The mode selection trial (MOST) in sinus node dysfunction: design, rationale, and baseline characteristics of the first 1000 patients
G A Lamas, K Lee, M Sweeney, et al.
Psychological Science
|
February 26, 2016
When Is an Adolescent an Adult? Assessing Cognitive Control in Emotional and Nonemotional Contexts
Alexandra O Cohen, Kaitlyn Breiner, Laurence Steinberg, et al.
Page
of 32